{"id": "article-17423_0", "title": "Alzheimer Disease -- Continuing Education Activity", "content": "This Continuing Medical Education (CME) activity provides healthcare professionals with the latest updates and evidence-based practices for diagnosing and managing Alzheimer's disease, a progressive neurodegenerative disorder affecting millions worldwide. Through a comprehensive and interprofessional approach, participants will gain valuable insights into the clinical features, biomarkers, and neuroimaging for early detection, as well as pharmacological and non-pharmacological interventions to support cognitive function and improve patient care. The activity also addresses the coordination of interprofessional teams, patient education, and emerging disease-modifying therapies.", "contents": "Alzheimer Disease -- Continuing Education Activity. This Continuing Medical Education (CME) activity provides healthcare professionals with the latest updates and evidence-based practices for diagnosing and managing Alzheimer's disease, a progressive neurodegenerative disorder affecting millions worldwide. Through a comprehensive and interprofessional approach, participants will gain valuable insights into the clinical features, biomarkers, and neuroimaging for early detection, as well as pharmacological and non-pharmacological interventions to support cognitive function and improve patient care. The activity also addresses the coordination of interprofessional teams, patient education, and emerging disease-modifying therapies."}
{"id": "article-17423_1", "title": "Alzheimer Disease -- Continuing Education Activity", "content": "Objectives: Identify early signs and symptoms of Alzheimer disease in patients, including memory impairment, cognitive decline, and behavioral changes. Implement evidence-based treatment approaches, including pharmacological therapies and non-pharmacological interventions, to manage cognitive and behavioral symptoms. Select appropriate resources and educational materials to empower patients and caregivers with accurate information about Alzheimer disease and its management. Collaborate with other healthcare professionals and community resources to provide comprehensive care and support for Alzheimer disease patients throughout the disease trajectory. Access free multiple choice questions on this topic.", "contents": "Alzheimer Disease -- Continuing Education Activity. Objectives: Identify early signs and symptoms of Alzheimer disease in patients, including memory impairment, cognitive decline, and behavioral changes. Implement evidence-based treatment approaches, including pharmacological therapies and non-pharmacological interventions, to manage cognitive and behavioral symptoms. Select appropriate resources and educational materials to empower patients and caregivers with accurate information about Alzheimer disease and its management. Collaborate with other healthcare professionals and community resources to provide comprehensive care and support for Alzheimer disease patients throughout the disease trajectory. Access free multiple choice questions on this topic."}
{"id": "article-17423_2", "title": "Alzheimer Disease -- Introduction", "content": "Dementia is a general term used to describe a significant decline in cognitive ability that interferes with a person's activities of daily living. Alzheimer disease (AD) is the most prevalent type of dementia, accounting for at least two-thirds of cases in\u00a0individuals aged 65 and older.\u00a0AD is a neurodegenerative\u00a0condition with insidious onset and\u00a0progressive impairment of behavioral and cognitive functions. These functions\u00a0include memory, comprehension, language, attention, reasoning, and judgment. While\u00a0AD does not directly cause death, it\u00a0substantially\u00a0raises vulnerability to other complications,\u00a0which can eventually lead\u00a0to a person's death.", "contents": "Alzheimer Disease -- Introduction. Dementia is a general term used to describe a significant decline in cognitive ability that interferes with a person's activities of daily living. Alzheimer disease (AD) is the most prevalent type of dementia, accounting for at least two-thirds of cases in\u00a0individuals aged 65 and older.\u00a0AD is a neurodegenerative\u00a0condition with insidious onset and\u00a0progressive impairment of behavioral and cognitive functions. These functions\u00a0include memory, comprehension, language, attention, reasoning, and judgment. While\u00a0AD does not directly cause death, it\u00a0substantially\u00a0raises vulnerability to other complications,\u00a0which can eventually lead\u00a0to a person's death."}
{"id": "article-17423_3", "title": "Alzheimer Disease -- Introduction", "content": "According to\u00a0Centers for Disease Control and Prevention (CDC) data,\u00a0AD is ranked as the seventh leading cause of death in the United States in 2022,\u00a0while COVID-19\u00a0ranked fourth. Before the COVID-19 pandemic, AD was the sixth leading cause of death following stroke. [1] . AD typically manifests\u00a0after age 65, referred to as late-onset AD (LOAD). However, early-onset AD (EOAD), occurring before 65, is less common\u00a0and seen in about 5% of\u00a0AD patients. EOAD often\u00a0exhibits\u00a0atypical symptoms, and its diagnosis is usually delayed,\u00a0leading to a more aggressive disease course. [2]", "contents": "Alzheimer Disease -- Introduction. According to\u00a0Centers for Disease Control and Prevention (CDC) data,\u00a0AD is ranked as the seventh leading cause of death in the United States in 2022,\u00a0while COVID-19\u00a0ranked fourth. Before the COVID-19 pandemic, AD was the sixth leading cause of death following stroke. [1] . AD typically manifests\u00a0after age 65, referred to as late-onset AD (LOAD). However, early-onset AD (EOAD), occurring before 65, is less common\u00a0and seen in about 5% of\u00a0AD patients. EOAD often\u00a0exhibits\u00a0atypical symptoms, and its diagnosis is usually delayed,\u00a0leading to a more aggressive disease course. [2]"}
{"id": "article-17423_4", "title": "Alzheimer Disease -- Introduction", "content": "Significant\u00a0progress\u00a0has been made in developing biomarkers for specific and early diagnosis of AD over the past decade. These biomarkers include neuroimaging markers obtained through amyloid and tau PET scans, cerebrospinal fluid (CSF), and plasma markers, such as amyloid, tau, and phospho-tau levels. [3]", "contents": "Alzheimer Disease -- Introduction. Significant\u00a0progress\u00a0has been made in developing biomarkers for specific and early diagnosis of AD over the past decade. These biomarkers include neuroimaging markers obtained through amyloid and tau PET scans, cerebrospinal fluid (CSF), and plasma markers, such as amyloid, tau, and phospho-tau levels. [3]"}
{"id": "article-17423_5", "title": "Alzheimer Disease -- Introduction", "content": "There is no cure for\u00a0AD, although there are treatments available that may\u00a0alleviate and manage some of its symptoms. In recent years, there have been significant advancements in the development of medications that aim to moderate the progression of the disease, particularly with the discovery of new disease biomarkers. [3]", "contents": "Alzheimer Disease -- Introduction. There is no cure for\u00a0AD, although there are treatments available that may\u00a0alleviate and manage some of its symptoms. In recent years, there have been significant advancements in the development of medications that aim to moderate the progression of the disease, particularly with the discovery of new disease biomarkers. [3]"}
{"id": "article-17423_6", "title": "Alzheimer Disease -- Introduction", "content": "The symptoms of\u00a0AD can vary depending on the stage of the disease.\u00a0AD is classified into different stages based on the level of cognitive impairment and disability experienced by individuals. These stages include the preclinical or presymptomatic stage, mild cognitive impairment, and dementia stage. The dementia stage is further divided into mild, moderate, and severe stages\u00a0(see Graph. AD Stages from Preclinical to Severe Disease). [4] This staging system is distinct from the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) for AD. [5]", "contents": "Alzheimer Disease -- Introduction. The symptoms of\u00a0AD can vary depending on the stage of the disease.\u00a0AD is classified into different stages based on the level of cognitive impairment and disability experienced by individuals. These stages include the preclinical or presymptomatic stage, mild cognitive impairment, and dementia stage. The dementia stage is further divided into mild, moderate, and severe stages\u00a0(see Graph. AD Stages from Preclinical to Severe Disease). [4] This staging system is distinct from the diagnostic criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) for AD. [5]"}
{"id": "article-17423_7", "title": "Alzheimer Disease -- Introduction", "content": "Episodic short-term memory loss is the initial and most common presenting symptom of\u00a0typical AD. Individuals may have difficulty retaining new information while still\u00a0recalling long-term memories. Individuals may experience problem-solving, judgment, executive functioning,\u00a0and organizational skills impairments following short-term memory loss.", "contents": "Alzheimer Disease -- Introduction. Episodic short-term memory loss is the initial and most common presenting symptom of\u00a0typical AD. Individuals may have difficulty retaining new information while still\u00a0recalling long-term memories. Individuals may experience problem-solving, judgment, executive functioning,\u00a0and organizational skills impairments following short-term memory loss."}
{"id": "article-17423_8", "title": "Alzheimer Disease -- Introduction", "content": "They may struggle with tasks that require\u00a0multitasking and abstract thinking. In the early stages of the disease,\u00a0executive functioning impairments can range\u00a0from subtle to significant. Instrumental activities of daily living such as driving, financial management, cooking, and detailed\u00a0activity planning are affected relatively early in their dementia.", "contents": "Alzheimer Disease -- Introduction. They may struggle with tasks that require\u00a0multitasking and abstract thinking. In the early stages of the disease,\u00a0executive functioning impairments can range\u00a0from subtle to significant. Instrumental activities of daily living such as driving, financial management, cooking, and detailed\u00a0activity planning are affected relatively early in their dementia."}
{"id": "article-17423_9", "title": "Alzheimer Disease -- Introduction", "content": "These early signs of cognitive decline are followed\u00a0by language disorder and impaired visuospatial skills. Neuropsychiatric symptoms like apathy, social withdrawal, disinhibition, agitation, psychosis, and wandering are also common in the moderate to late stages. Difficulty performing learned motor tasks (dyspraxia), olfactory dysfunction, sleep disturbances, and extrapyramidal motor signs like dystonia, akathisia, and Parkinsonian symptoms occur late in the disease. Primitive reflexes, incontinence, and total dependence on caregivers follow this. [6] [7] [8]", "contents": "Alzheimer Disease -- Introduction. These early signs of cognitive decline are followed\u00a0by language disorder and impaired visuospatial skills. Neuropsychiatric symptoms like apathy, social withdrawal, disinhibition, agitation, psychosis, and wandering are also common in the moderate to late stages. Difficulty performing learned motor tasks (dyspraxia), olfactory dysfunction, sleep disturbances, and extrapyramidal motor signs like dystonia, akathisia, and Parkinsonian symptoms occur late in the disease. Primitive reflexes, incontinence, and total dependence on caregivers follow this. [6] [7] [8]"}
{"id": "article-17423_10", "title": "Alzheimer Disease -- Etiology", "content": "Alzheimer disease\u00a0is characterized by gradual and progressive neurodegeneration caused by neuronal cell death. The neurodegenerative\u00a0process typically\u00a0begins in the entorhinal cortex\u00a0within the hippocampus. Genetic factors\u00a0have been identified to contribute\u00a0to both early and late-onset AD. Trisomy 21, for example, is a risk factor\u00a0associated with early-onset dementia.", "contents": "Alzheimer Disease -- Etiology. Alzheimer disease\u00a0is characterized by gradual and progressive neurodegeneration caused by neuronal cell death. The neurodegenerative\u00a0process typically\u00a0begins in the entorhinal cortex\u00a0within the hippocampus. Genetic factors\u00a0have been identified to contribute\u00a0to both early and late-onset AD. Trisomy 21, for example, is a risk factor\u00a0associated with early-onset dementia."}
{"id": "article-17423_11", "title": "Alzheimer Disease -- Etiology", "content": "AD is a multifactorial\u00a0condition associated with many known risk factors. The most significant factor is age, with advancing age being the primary contributor. The prevalence of AD approximately doubles with every\u00a05 years increase in age starting from age 65.", "contents": "Alzheimer Disease -- Etiology. AD is a multifactorial\u00a0condition associated with many known risk factors. The most significant factor is age, with advancing age being the primary contributor. The prevalence of AD approximately doubles with every\u00a05 years increase in age starting from age 65."}
{"id": "article-17423_12", "title": "Alzheimer Disease -- Etiology", "content": "Cardiovascular diseases (CVD) are recognized as\u00a0significant risk factors for AD. They increase the risk of developing AD and contribute to the risk of dementia caused by strokes or vascular dementia. CVD is\u00a0increasingly\u00a0recognized as a modifiable risk factor for AD. [9]", "contents": "Alzheimer Disease -- Etiology. Cardiovascular diseases (CVD) are recognized as\u00a0significant risk factors for AD. They increase the risk of developing AD and contribute to the risk of dementia caused by strokes or vascular dementia. CVD is\u00a0increasingly\u00a0recognized as a modifiable risk factor for AD. [9]"}
{"id": "article-17423_13", "title": "Alzheimer Disease -- Etiology", "content": "Obesity and diabetes are also important modifiable risk factors for AD. Obesity can impair\u00a0glucose tolerance and increase the risk of developing type II diabetes. Chronic hyperglycemia\u00a0can lead to\u00a0cognitive impairment by\u00a0promoting the accumulation of\u00a0beta-amyloid (A-beta) and neuroinflammation. Obesity further\u00a0amplifies the risk by triggering the release of pro-inflammatory cytokines and promoting insulin resistance. [10]", "contents": "Alzheimer Disease -- Etiology. Obesity and diabetes are also important modifiable risk factors for AD. Obesity can impair\u00a0glucose tolerance and increase the risk of developing type II diabetes. Chronic hyperglycemia\u00a0can lead to\u00a0cognitive impairment by\u00a0promoting the accumulation of\u00a0beta-amyloid (A-beta) and neuroinflammation. Obesity further\u00a0amplifies the risk by triggering the release of pro-inflammatory cytokines and promoting insulin resistance. [10]"}
{"id": "article-17423_14", "title": "Alzheimer Disease -- Etiology", "content": "Other potential risk factors for AD include traumatic head injury, depression, cardiovascular and cerebrovascular disease, higher parental age at birth, smoking, family history of dementia, increased homocysteine levels, and the presence of the APOE e4 allele. Having a first-degree relative with\u00a0AD increases the risk of developing the disease\u00a0by 10% to 30%. Individuals with\u00a02 or more siblings with late-onset\u00a0AD\u00a0face a\u00a03-fold higher risk than the general population. [11] [12] [13]", "contents": "Alzheimer Disease -- Etiology. Other potential risk factors for AD include traumatic head injury, depression, cardiovascular and cerebrovascular disease, higher parental age at birth, smoking, family history of dementia, increased homocysteine levels, and the presence of the APOE e4 allele. Having a first-degree relative with\u00a0AD increases the risk of developing the disease\u00a0by 10% to 30%. Individuals with\u00a02 or more siblings with late-onset\u00a0AD\u00a0face a\u00a03-fold higher risk than the general population. [11] [12] [13]"}
{"id": "article-17423_15", "title": "Alzheimer Disease -- Etiology", "content": "Several factors have been identified that may\u00a0potentially reduce the\u00a0risk of developing AD. These include higher education, estrogen use in women, anti-inflammatory agents, leisure activities\u00a0such as reading or playing musical instruments, maintaining a healthy diet, and regular aerobic exercise.", "contents": "Alzheimer Disease -- Etiology. Several factors have been identified that may\u00a0potentially reduce the\u00a0risk of developing AD. These include higher education, estrogen use in women, anti-inflammatory agents, leisure activities\u00a0such as reading or playing musical instruments, maintaining a healthy diet, and regular aerobic exercise."}
{"id": "article-17423_16", "title": "Alzheimer Disease -- Epidemiology", "content": "AD\u00a0is predominantly\u00a0observed in older individuals. The global prevalence of dementia was reported to be\u00a020.3 million\u00a0in 1990, and it significantly increased to 43.8 million in 2016, representing a remarkable rise of 116%. From 1990 to 2019, the incidence and prevalence of Alzheimer disease and other dementias\u00a0rose by 147.95% and 160.84%, respectively. Projections indicate that the number of people affected by dementia is expected to reach 150 million by 2050,\u00a0representing\u00a0a 4-fold increase. [14]", "contents": "Alzheimer Disease -- Epidemiology. AD\u00a0is predominantly\u00a0observed in older individuals. The global prevalence of dementia was reported to be\u00a020.3 million\u00a0in 1990, and it significantly increased to 43.8 million in 2016, representing a remarkable rise of 116%. From 1990 to 2019, the incidence and prevalence of Alzheimer disease and other dementias\u00a0rose by 147.95% and 160.84%, respectively. Projections indicate that the number of people affected by dementia is expected to reach 150 million by 2050,\u00a0representing\u00a0a 4-fold increase. [14]"}
{"id": "article-17423_17", "title": "Alzheimer Disease -- Epidemiology", "content": "The incidence of Alzheimer's disease doubles every 5 years after age 65. Age-specific incidence rates significantly increase from less than 1% yearly before 65 to 6% per year after 85. Prevalence rates increase from 10% after the age of 65 to 40% after 85. Incidence rates of\u00a0Alzheimer's disease\u00a0are slightly higher for women, especially after 85. [15]", "contents": "Alzheimer Disease -- Epidemiology. The incidence of Alzheimer's disease doubles every 5 years after age 65. Age-specific incidence rates significantly increase from less than 1% yearly before 65 to 6% per year after 85. Prevalence rates increase from 10% after the age of 65 to 40% after 85. Incidence rates of\u00a0Alzheimer's disease\u00a0are slightly higher for women, especially after 85. [15]"}
{"id": "article-17423_18", "title": "Alzheimer Disease -- Pathophysiology", "content": "Alzheimer disease is characterized pathologically by an accumulation of abnormal neuritic plaques and neurofibrillary tangles in the brain. These pathological changes are accompanied by a loss of neurons, particularly cholinergic neurons in the basal forebrain and the neocortex. Two prominent pathophysiological hypotheses have been proposed based on these pathological findings: [16]", "contents": "Alzheimer Disease -- Pathophysiology. Alzheimer disease is characterized pathologically by an accumulation of abnormal neuritic plaques and neurofibrillary tangles in the brain. These pathological changes are accompanied by a loss of neurons, particularly cholinergic neurons in the basal forebrain and the neocortex. Two prominent pathophysiological hypotheses have been proposed based on these pathological findings: [16]"}
{"id": "article-17423_19", "title": "Alzheimer Disease -- Pathophysiology", "content": "The Cholinergic Hypothesis proposes that the reduced levels of acetylcholine (ACh) in the brain, resulting from neuronal loss in the Nucleus Basalis of Meynert, play a significant role in AD development. This hypothesis stems from the early loss of cholinergic neurons in AD, which highlights the importance of ACh in cognitive processes.\u00a0Beta-amyloid is believed to negatively affect cholinergic function by causing cholinergic synaptic loss and impaired ACh release. Anticholinergics also adversely affect memory in elderly patients clinically. [17]", "contents": "Alzheimer Disease -- Pathophysiology. The Cholinergic Hypothesis proposes that the reduced levels of acetylcholine (ACh) in the brain, resulting from neuronal loss in the Nucleus Basalis of Meynert, play a significant role in AD development. This hypothesis stems from the early loss of cholinergic neurons in AD, which highlights the importance of ACh in cognitive processes.\u00a0Beta-amyloid is believed to negatively affect cholinergic function by causing cholinergic synaptic loss and impaired ACh release. Anticholinergics also adversely affect memory in elderly patients clinically. [17]"}
{"id": "article-17423_20", "title": "Alzheimer Disease -- Pathophysiology", "content": "The Amyloid Hypothesis is currently the most widely\u00a0accepted pathophysiological mechanism for AD, especially in cases of inherited AD. The amyloid hypothesis suggests that amyloid beta (A\u03b2) peptide is derived from amyloid precursor protein (APP) through the actions of \u03b2- and \u03b3-secretase enzymes. Usually, APP is cleaved by either alpha\u00a0or beta-secretase, and the tiny fragments formed by them are not toxic to neurons\u2014however, sequential cleavage by beta and then gamma-secretase results in 42 amino acid peptides (A\u03b242). Elevation in levels of A\u03b242 leads to aggregation of amyloid that causes neuronal toxicity. A\u03b242 favors the formation of aggregated fibrillary amyloid protein over normal APP degradation. [18]", "contents": "Alzheimer Disease -- Pathophysiology. The Amyloid Hypothesis is currently the most widely\u00a0accepted pathophysiological mechanism for AD, especially in cases of inherited AD. The amyloid hypothesis suggests that amyloid beta (A\u03b2) peptide is derived from amyloid precursor protein (APP) through the actions of \u03b2- and \u03b3-secretase enzymes. Usually, APP is cleaved by either alpha\u00a0or beta-secretase, and the tiny fragments formed by them are not toxic to neurons\u2014however, sequential cleavage by beta and then gamma-secretase results in 42 amino acid peptides (A\u03b242). Elevation in levels of A\u03b242 leads to aggregation of amyloid that causes neuronal toxicity. A\u03b242 favors the formation of aggregated fibrillary amyloid protein over normal APP degradation. [18]"}
{"id": "article-17423_21", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "Down Syndrome, a genetic condition caused by trisomy 21, is strongly linked to the amyloid hypothesis in the context of AD research. In Down Syndrome, individuals have an extra copy of chromosome 21, leading to an additional copy of the APP gene.", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. Down Syndrome, a genetic condition caused by trisomy 21, is strongly linked to the amyloid hypothesis in the context of AD research. In Down Syndrome, individuals have an extra copy of chromosome 21, leading to an additional copy of the APP gene."}
{"id": "article-17423_22", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "Due to this genetic duplication, individuals with Down Syndrome have higher levels of APP, which increases the production of amyloid-beta (A\u03b2) peptides. As a result, individuals with Down Syndrome are at a significantly increased risk of developing AD. It is estimated that approximately 40% to 80% of patients with Down Syndrome experience clinical AD by the fifth to sixth decade of life, and nearly 100% of them exhibit AD pathology, such as amyloid plaques and neurofibrillary tangles. [19]", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. Due to this genetic duplication, individuals with Down Syndrome have higher levels of APP, which increases the production of amyloid-beta (A\u03b2) peptides. As a result, individuals with Down Syndrome are at a significantly increased risk of developing AD. It is estimated that approximately 40% to 80% of patients with Down Syndrome experience clinical AD by the fifth to sixth decade of life, and nearly 100% of them exhibit AD pathology, such as amyloid plaques and neurofibrillary tangles. [19]"}
{"id": "article-17423_23", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "AD\u00a0can be inherited as an autosomal dominant disorder with nearly complete penetrance. This form of the disease is linked to mutations in 3 genes:  the AAP gene on chromosome 21, Presenilin1 (PSEN1) on chromosome 14, and Presenilin 2 (PSEN2) on chromosome 1.", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. AD\u00a0can be inherited as an autosomal dominant disorder with nearly complete penetrance. This form of the disease is linked to mutations in 3 genes:  the AAP gene on chromosome 21, Presenilin1 (PSEN1) on chromosome 14, and Presenilin 2 (PSEN2) on chromosome 1."}
{"id": "article-17423_24", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "APP mutations may lead to increased\u00a0production and\u00a0accumulation\u00a0of A\u03b2. On the other hand,\u00a0PSEN1 and PSEN2 mutations interfere with the processing of gamma-secretase, leading to the aggregation of A\u03b2 in the brain.", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. APP mutations may lead to increased\u00a0production and\u00a0accumulation\u00a0of A\u03b2. On the other hand,\u00a0PSEN1 and PSEN2 mutations interfere with the processing of gamma-secretase, leading to the aggregation of A\u03b2 in the brain."}
{"id": "article-17423_25", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "Although these mutations are relatively rare, accounting for approximately 5% to 10% of all AD cases, they are strongly associated with early-onset forms of the disease. The PSEN1 mutation is the most common, accounting for about 5% of all AD cases. [20]", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. Although these mutations are relatively rare, accounting for approximately 5% to 10% of all AD cases, they are strongly associated with early-onset forms of the disease. The PSEN1 mutation is the most common, accounting for about 5% of all AD cases. [20]"}
{"id": "article-17423_26", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "Apolipoprotein E (APOE) is a lipid metabolism regulator with an affinity for\u00a0beta-amyloid\u00a0protein. There are\u00a03 alleles for the Apolipoprotein E gene: \u03b52,\u00a0\u03b53, and\u00a0\u03b54. The \u03b54 allele of the APOE gene\u00a0has been\u00a0identified as a significant genetic risk factor for LOAD. Heterozygous carriers of the\u00a0\u03b54 allele have a 3 times increased risk, while homozygous carriers face 15 times increased risk of developing AD.\u00a0In patients\u00a0with EOAD,\u00a0the risk is\u00a0even more pronounced in homozygous \u03b54 carriers and heterozygous \u03b54 carriers with a positive family history of AD.", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. Apolipoprotein E (APOE) is a lipid metabolism regulator with an affinity for\u00a0beta-amyloid\u00a0protein. There are\u00a03 alleles for the Apolipoprotein E gene: \u03b52,\u00a0\u03b53, and\u00a0\u03b54. The \u03b54 allele of the APOE gene\u00a0has been\u00a0identified as a significant genetic risk factor for LOAD. Heterozygous carriers of the\u00a0\u03b54 allele have a 3 times increased risk, while homozygous carriers face 15 times increased risk of developing AD.\u00a0In patients\u00a0with EOAD,\u00a0the risk is\u00a0even more pronounced in homozygous \u03b54 carriers and heterozygous \u03b54 carriers with a positive family history of AD."}
{"id": "article-17423_27", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "The presence of the APOE e4 allele is\u00a0considered one of\u00a0the most crucial risk factors for sporadic Alzheimer disease. [20] While the \u03b54 allele increases the risk of developing the disease, it is essential to recognize that not everyone with the \u03b54 allele will develop AD, and many other factors play a role in the complex etiology of the disease.", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. The presence of the APOE e4 allele is\u00a0considered one of\u00a0the most crucial risk factors for sporadic Alzheimer disease. [20] While the \u03b54 allele increases the risk of developing the disease, it is essential to recognize that not everyone with the \u03b54 allele will develop AD, and many other factors play a role in the complex etiology of the disease."}
{"id": "article-17423_28", "title": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease", "content": "Variants in the gene for the sortilin receptor, SORT1, which is essential for transporting APP from the cell surface to the Golgi-endoplasmic reticulum complex, have been found in familial and sporadic forms of AD. [11]", "contents": "Alzheimer Disease -- Pathophysiology -- Genetic Basis of\u00a0Alzheimer Disease. Variants in the gene for the sortilin receptor, SORT1, which is essential for transporting APP from the cell surface to the Golgi-endoplasmic reticulum complex, have been found in familial and sporadic forms of AD. [11]"}
{"id": "article-17423_29", "title": "Alzheimer Disease -- Histopathology", "content": "The typical histopathology\u00a0of AD\u00a0is characterized by the presence\u00a0of\u00a03 main elements: [21]", "contents": "Alzheimer Disease -- Histopathology. The typical histopathology\u00a0of AD\u00a0is characterized by the presence\u00a0of\u00a03 main elements: [21]"}
{"id": "article-17423_30", "title": "Alzheimer Disease -- Histopathology", "content": "Neuritic Plaques: Neuritic plaques\u00a0are spherical microscopic lesions featuring a core of extracellular amyloid beta-peptide\u00a0(A\u03b2) surrounded by enlarged axonal endings.\u00a0These A\u03b2 depositions occur around meningeal and cerebral vessels and within the cortical gray matter in individuals with AD. Gray matter deposits are multifocal and coalesce, forming milliary structures called plaques.\u00a0However, in some cases, brain scans have revealed the presence of amyloid plaques in some individuals without dementia. In contrast, other patients with diagnosed dementia who underwent multiple brain scans did not show evidence of plaques.", "contents": "Alzheimer Disease -- Histopathology. Neuritic Plaques: Neuritic plaques\u00a0are spherical microscopic lesions featuring a core of extracellular amyloid beta-peptide\u00a0(A\u03b2) surrounded by enlarged axonal endings.\u00a0These A\u03b2 depositions occur around meningeal and cerebral vessels and within the cortical gray matter in individuals with AD. Gray matter deposits are multifocal and coalesce, forming milliary structures called plaques.\u00a0However, in some cases, brain scans have revealed the presence of amyloid plaques in some individuals without dementia. In contrast, other patients with diagnosed dementia who underwent multiple brain scans did not show evidence of plaques."}
{"id": "article-17423_31", "title": "Alzheimer Disease -- Histopathology", "content": "Neurofibrillary Tangles: Neurofibrillary tangles\u00a0are fibrillary intracytoplasmic structures that form inside neurons\u00a0and are composed of\u00a0a protein called tau. The primary function of the tau protein is to stabilize axonal microtubules. Microtubules run along neuronal axons and are essential for intracellular transport. Tau helps maintain the integrity of microtubules and aids in their assembly along neuronal axons.", "contents": "Alzheimer Disease -- Histopathology. Neurofibrillary Tangles: Neurofibrillary tangles\u00a0are fibrillary intracytoplasmic structures that form inside neurons\u00a0and are composed of\u00a0a protein called tau. The primary function of the tau protein is to stabilize axonal microtubules. Microtubules run along neuronal axons and are essential for intracellular transport. Tau helps maintain the integrity of microtubules and aids in their assembly along neuronal axons."}
{"id": "article-17423_32", "title": "Alzheimer Disease -- Histopathology", "content": "In AD,\u00a0the aggregation of extracellular\u00a0beta-amyloid leads to hyperphosphorylation of tau. This abnormal phosphorylation causes tau to become misfolded and form aggregates within the neurons. These tau aggregates\u00a0take the shape of twisted paired helical filaments known as neurofibrillary tangles. Neurofibrillary tangles first appear in the hippocampus and\u00a0subsequently spread throughout the cerebral cortex. Tau-aggregates are deposited within the neurons.", "contents": "Alzheimer Disease -- Histopathology. In AD,\u00a0the aggregation of extracellular\u00a0beta-amyloid leads to hyperphosphorylation of tau. This abnormal phosphorylation causes tau to become misfolded and form aggregates within the neurons. These tau aggregates\u00a0take the shape of twisted paired helical filaments known as neurofibrillary tangles. Neurofibrillary tangles first appear in the hippocampus and\u00a0subsequently spread throughout the cerebral cortex. Tau-aggregates are deposited within the neurons."}
{"id": "article-17423_33", "title": "Alzheimer Disease -- Histopathology", "content": "Cortical Neuronal Degeneration: Among these degenerative changes, granulovacuolar degeneration of hippocampal pyramidal neurons is commonly observed. Cognitive decline in AD appears to be more closely related to a decrease in the density of presynaptic boutons from pyramidal neurons in specific layers of the cerebral cortex, particularly in laminae III and IV. The reduction in their density may have a more significant impact on cognitive function than the mere increase in the number of plaques characteristic of AD.", "contents": "Alzheimer Disease -- Histopathology. Cortical Neuronal Degeneration: Among these degenerative changes, granulovacuolar degeneration of hippocampal pyramidal neurons is commonly observed. Cognitive decline in AD appears to be more closely related to a decrease in the density of presynaptic boutons from pyramidal neurons in specific layers of the cerebral cortex, particularly in laminae III and IV. The reduction in their density may have a more significant impact on cognitive function than the mere increase in the number of plaques characteristic of AD."}
{"id": "article-17423_34", "title": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging", "content": "A staging system known as the\u00a0Braak and Braak staging has been developed to categorize the\u00a0topographical progression of neurofibrillary tangles into 6 stages. This staging method is widely recognized and is integral to the diagnostic criteria for\u00a0AD provided by the National Institute on Aging and Reagan Institute.", "contents": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging. A staging system known as the\u00a0Braak and Braak staging has been developed to categorize the\u00a0topographical progression of neurofibrillary tangles into 6 stages. This staging method is widely recognized and is integral to the diagnostic criteria for\u00a0AD provided by the National Institute on Aging and Reagan Institute."}
{"id": "article-17423_35", "title": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging", "content": "Neurofibrillary\u00a0tangles have\u00a0demonstrated a stronger correlation with\u00a0AD severity\u00a0than plaques. [22] This means\u00a0that the amount of tau deposits in the brains of patients with AD correlates better with dementia severity than the amount of amyloid deposits. However, amyloid is a better-defining pathology for AD than other forms of dementia.", "contents": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging. Neurofibrillary\u00a0tangles have\u00a0demonstrated a stronger correlation with\u00a0AD severity\u00a0than plaques. [22] This means\u00a0that the amount of tau deposits in the brains of patients with AD correlates better with dementia severity than the amount of amyloid deposits. However, amyloid is a better-defining pathology for AD than other forms of dementia."}
{"id": "article-17423_36", "title": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging", "content": "The relationship between amyloid and tau in the pathogenesis of AD is often\u00a0likened to a \"trigger and bullet\" scenario. [23] Amyloid is considered the trigger that initiates the disease process. At the same time, tau, in the form of neurofibrillary tangles, acts as the bullet that leads to neurodegeneration and cognitive decline.", "contents": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging. The relationship between amyloid and tau in the pathogenesis of AD is often\u00a0likened to a \"trigger and bullet\" scenario. [23] Amyloid is considered the trigger that initiates the disease process. At the same time, tau, in the form of neurofibrillary tangles, acts as the bullet that leads to neurodegeneration and cognitive decline."}
{"id": "article-17423_37", "title": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging", "content": "Accumulation of A\u03b2 is a common feature in AD, with a higher prevalence of the more soluble A\u03b240 than the A\u03b242. In some AD patients, A\u03b2 accumulates in the intracranial blood vessels, leading to the pathology\u00a0known as cerebral amyloid angiopathy(CAA).\u00a0The presence of CAA in AD has clinical implications, as it is associated with more significant cognitive impairment and possibly faster cognitive decline in affected individuals. [24]", "contents": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging. Accumulation of A\u03b2 is a common feature in AD, with a higher prevalence of the more soluble A\u03b240 than the A\u03b242. In some AD patients, A\u03b2 accumulates in the intracranial blood vessels, leading to the pathology\u00a0known as cerebral amyloid angiopathy(CAA).\u00a0The presence of CAA in AD has clinical implications, as it is associated with more significant cognitive impairment and possibly faster cognitive decline in affected individuals. [24]"}
{"id": "article-17423_38", "title": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging", "content": "On the other hand, vascular contribution to the neurodegenerative process of\u00a0AD is not yet fully understood. However, research suggests that subcortical infarcts can increase the risk of dementia by 4-fold. Additionally, cerebrovascular disease can exaggerate the\u00a0severity of\u00a0dementia and accelerate its progression. [25] [26] [27]", "contents": "Alzheimer Disease -- Histopathology -- Braak and Braak Staging. On the other hand, vascular contribution to the neurodegenerative process of\u00a0AD is not yet fully understood. However, research suggests that subcortical infarcts can increase the risk of dementia by 4-fold. Additionally, cerebrovascular disease can exaggerate the\u00a0severity of\u00a0dementia and accelerate its progression. [25] [26] [27]"}
{"id": "article-17423_39", "title": "Alzheimer Disease -- History and Physical", "content": "Thorough history-taking and a comprehensive physical examination are crucial for diagnosing AD. Additionally, gathering information from family and caregivers is vital as some patients may lack insight into their disease. Assessing\u00a0functional abilities, including basic activities of daily living(ADL) and instrumental activities of daily living (IADL), provides valuable insights into the patient's cognitive and functional status. IADLs involve more complex planning and cognitive skills such as shopping, managing finances, tax filing, preparing meals, and\u00a0housekeeping.", "contents": "Alzheimer Disease -- History and Physical. Thorough history-taking and a comprehensive physical examination are crucial for diagnosing AD. Additionally, gathering information from family and caregivers is vital as some patients may lack insight into their disease. Assessing\u00a0functional abilities, including basic activities of daily living(ADL) and instrumental activities of daily living (IADL), provides valuable insights into the patient's cognitive and functional status. IADLs involve more complex planning and cognitive skills such as shopping, managing finances, tax filing, preparing meals, and\u00a0housekeeping."}
{"id": "article-17423_40", "title": "Alzheimer Disease -- History and Physical", "content": "Obtaining\u00a0information about the onset, pattern, and\u00a0tempo\u00a0of disease progression is essential for understanding the nature of the condition. This includes noting changes in memory, cognition, behavior, or functional abilities over time. The patient's medication history is also critical, as certain medications, especially those with anticholinergic effects, may impact cognitive function and should be considered in the evaluation.", "contents": "Alzheimer Disease -- History and Physical. Obtaining\u00a0information about the onset, pattern, and\u00a0tempo\u00a0of disease progression is essential for understanding the nature of the condition. This includes noting changes in memory, cognition, behavior, or functional abilities over time. The patient's medication history is also critical, as certain medications, especially those with anticholinergic effects, may impact cognitive function and should be considered in the evaluation."}
{"id": "article-17423_41", "title": "Alzheimer Disease -- History and Physical", "content": "In addition to medical history, it is essential to inquire about the patient's social history, including alcohol use and any history of street drug use. These factors can potentially influence cognitive function and should be considered during the diagnostic process. [28]", "contents": "Alzheimer Disease -- History and Physical. In addition to medical history, it is essential to inquire about the patient's social history, including alcohol use and any history of street drug use. These factors can potentially influence cognitive function and should be considered during the diagnostic process. [28]"}
{"id": "article-17423_42", "title": "Alzheimer Disease -- History and Physical", "content": "A comprehensive physical exam, including a detailed neurological exam and mental status assessment, is essential to evaluate the AD stage and rule out other potential conditions. A complete\u00a0clinical assessment can provide a reasonable level of diagnostic accuracy for most patients.", "contents": "Alzheimer Disease -- History and Physical. A comprehensive physical exam, including a detailed neurological exam and mental status assessment, is essential to evaluate the AD stage and rule out other potential conditions. A complete\u00a0clinical assessment can provide a reasonable level of diagnostic accuracy for most patients."}
{"id": "article-17423_43", "title": "Alzheimer Disease -- History and Physical", "content": "A detailed neurological examination is essential to rule out other potential conditions. In\u00a0AD, the neurological exam typically appears normal, except for anosmia. Anosmia is also found in patients with Parkinson disease, dementia with Lewy bodies, and\u00a0traumatic brain injury (TBI) with or without dementia, but not in individuals\u00a0with vascular cognitive impairment (VCI) or depression.", "contents": "Alzheimer Disease -- History and Physical. A detailed neurological examination is essential to rule out other potential conditions. In\u00a0AD, the neurological exam typically appears normal, except for anosmia. Anosmia is also found in patients with Parkinson disease, dementia with Lewy bodies, and\u00a0traumatic brain injury (TBI) with or without dementia, but not in individuals\u00a0with vascular cognitive impairment (VCI) or depression."}
{"id": "article-17423_44", "title": "Alzheimer Disease -- History and Physical", "content": "A Mini-mental Status Exam (MMSE) or, preferably, a Montreal Cognitive Assessment Exam (MOCA) should be performed and documented as part of the cognitive neurological exam. The MOCA is more sensitive to\u00a0evaluating\u00a0patients with mild cognitive impairment than the MMSE. [29] [30] Another effective cognitive screening test for primary care physicians is the Mini-Cog exam, which involves a clock drawing test and 3-item recall. [31] Notably, the results of the Mini-Cog are not significantly influenced by the individual's level of education. In the advanced stages of AD, patients\u00a0may exhibit more focal neurological signs, including apraxia and aphasia, frontal release signs, and primitive reflexes.", "contents": "Alzheimer Disease -- History and Physical. A Mini-mental Status Exam (MMSE) or, preferably, a Montreal Cognitive Assessment Exam (MOCA) should be performed and documented as part of the cognitive neurological exam. The MOCA is more sensitive to\u00a0evaluating\u00a0patients with mild cognitive impairment than the MMSE. [29] [30] Another effective cognitive screening test for primary care physicians is the Mini-Cog exam, which involves a clock drawing test and 3-item recall. [31] Notably, the results of the Mini-Cog are not significantly influenced by the individual's level of education. In the advanced stages of AD, patients\u00a0may exhibit more focal neurological signs, including apraxia and aphasia, frontal release signs, and primitive reflexes."}
{"id": "article-17423_45", "title": "Alzheimer Disease -- History and Physical", "content": "Patients may become\u00a0mute and unresponsive\u00a0to verbal requests as the disease progresses, leading to increased dependence on caregivers. They may eventually become confined to bed and eventually enter\u00a0into a persistent vegetative state.", "contents": "Alzheimer Disease -- History and Physical. Patients may become\u00a0mute and unresponsive\u00a0to verbal requests as the disease progresses, leading to increased dependence on caregivers. They may eventually become confined to bed and eventually enter\u00a0into a persistent vegetative state."}
{"id": "article-17423_46", "title": "Alzheimer Disease -- History and Physical", "content": "During\u00a0a mental status examination, it is essential to assess various cognitive domains to evaluate the extent of cognitive decline in AD. These domains include concentration, attention, recent and remote memory, language skills, visuospatial functioning, praxis,\u00a0and executive functioning. These assessments help to evaluate the extent of cognitive decline. All follow-up visits for individuals with AD should include a\u00a0thorough mental status examination to\u00a0assess\u00a0disease progression and the development of neuropsychiatric symptoms.", "contents": "Alzheimer Disease -- History and Physical. During\u00a0a mental status examination, it is essential to assess various cognitive domains to evaluate the extent of cognitive decline in AD. These domains include concentration, attention, recent and remote memory, language skills, visuospatial functioning, praxis,\u00a0and executive functioning. These assessments help to evaluate the extent of cognitive decline. All follow-up visits for individuals with AD should include a\u00a0thorough mental status examination to\u00a0assess\u00a0disease progression and the development of neuropsychiatric symptoms."}
{"id": "article-17423_47", "title": "Alzheimer Disease -- Evaluation", "content": "From a primary care provider standpoint, when evaluating a patient suspected to be suffering from AD, the following tasks are essential: Review and confirm the medical and family history. Review the patient's medication list for medications that may potentially cause or worsen cognition. Perform a bedside cognitive assessment test, either an MMSE or MOCA, to evaluate the patient's cognitive function. Request blood tests to\u00a0rule out\u00a0any reversible causes of dementia", "contents": "Alzheimer Disease -- Evaluation. From a primary care provider standpoint, when evaluating a patient suspected to be suffering from AD, the following tasks are essential: Review and confirm the medical and family history. Review the patient's medication list for medications that may potentially cause or worsen cognition. Perform a bedside cognitive assessment test, either an MMSE or MOCA, to evaluate the patient's cognitive function. Request blood tests to\u00a0rule out\u00a0any reversible causes of dementia"}
{"id": "article-17423_48", "title": "Alzheimer Disease -- Evaluation", "content": "Routine laboratory tests do not reveal any specific abnormalities in AD. Complete blood count (CBC), complete metabolic\u00a0panel (CMP), thyroid-stimulating hormone (TSH), and vitamin B12 levels are commonly conducted to exclude other potential causes of cognitive impairment. [32] [33] [34]", "contents": "Alzheimer Disease -- Evaluation. Routine laboratory tests do not reveal any specific abnormalities in AD. Complete blood count (CBC), complete metabolic\u00a0panel (CMP), thyroid-stimulating hormone (TSH), and vitamin B12 levels are commonly conducted to exclude other potential causes of cognitive impairment. [32] [33] [34]"}
{"id": "article-17423_49", "title": "Alzheimer Disease -- Evaluation", "content": "A brain computed tomography (CT) may reveal findings of\u00a0cerebral atrophy and a widened third ventricle in individuals with AD. However, these findings are suggestive\u00a0but not specific to AD, as they can also be\u00a0present in other conditions\u00a0and even in individuals\u00a0experiencing normal age-related changes in the brain.", "contents": "Alzheimer Disease -- Evaluation. A brain computed tomography (CT) may reveal findings of\u00a0cerebral atrophy and a widened third ventricle in individuals with AD. However, these findings are suggestive\u00a0but not specific to AD, as they can also be\u00a0present in other conditions\u00a0and even in individuals\u00a0experiencing normal age-related changes in the brain."}
{"id": "article-17423_50", "title": "Alzheimer Disease -- Evaluation", "content": "Magnetic Resonance Imaging (MRI) is a superior structural neuroimaging modality compared to CT when evaluating individuals with dementia, including those suspected of having AD. In AD cases, MRI can reveal specific features compatible with the diagnosis. These include atrophy of the entorhinal cortex, followed by atrophy of the medial temporal cortex or hippocampi (see Image. Normal Versus AD Brain).", "contents": "Alzheimer Disease -- Evaluation. Magnetic Resonance Imaging (MRI) is a superior structural neuroimaging modality compared to CT when evaluating individuals with dementia, including those suspected of having AD. In AD cases, MRI can reveal specific features compatible with the diagnosis. These include atrophy of the entorhinal cortex, followed by atrophy of the medial temporal cortex or hippocampi (see Image. Normal Versus AD Brain)."}
{"id": "article-17423_51", "title": "Alzheimer Disease -- Evaluation", "content": "While MRI, like CT, may not make or confirm the diagnosis of AD, it\u00a0can be beneficial in identifying specific patterns indicative of other neurodegenerative disorders with dementia, such as frontotemporal lobar degeneration, or specific radiological signs of multisystem atrophy, Creutzfeld-Jacob disease, or progressive supranuclear palsy. [35]", "contents": "Alzheimer Disease -- Evaluation. While MRI, like CT, may not make or confirm the diagnosis of AD, it\u00a0can be beneficial in identifying specific patterns indicative of other neurodegenerative disorders with dementia, such as frontotemporal lobar degeneration, or specific radiological signs of multisystem atrophy, Creutzfeld-Jacob disease, or progressive supranuclear palsy. [35]"}
{"id": "article-17423_52", "title": "Alzheimer Disease -- Evaluation", "content": "More recently, volumetric MRI\u00a0has emerged as a valuable tool for precisely measuring changes in brain volume. In AD, volumetric MRI\u00a0can reveal shrinkage in the medial temporal lobe, particularly the hippocampus. This hippocampal atrophy is considered a characteristic feature of AD and is associated with memory decline.", "contents": "Alzheimer Disease -- Evaluation. More recently, volumetric MRI\u00a0has emerged as a valuable tool for precisely measuring changes in brain volume. In AD, volumetric MRI\u00a0can reveal shrinkage in the medial temporal lobe, particularly the hippocampus. This hippocampal atrophy is considered a characteristic feature of AD and is associated with memory decline."}
{"id": "article-17423_53", "title": "Alzheimer Disease -- Evaluation", "content": "However, hippocampal atrophy is also linked to normal age-related memory decline, so the use of volumetric MRI for early detection of\u00a0AD and distinguishing it from normal aging-related changes is still a subject of debate and research. A definite role for volumetric MRI to aid the diagnosis of AD is not yet fully established. [36]", "contents": "Alzheimer Disease -- Evaluation. However, hippocampal atrophy is also linked to normal age-related memory decline, so the use of volumetric MRI for early detection of\u00a0AD and distinguishing it from normal aging-related changes is still a subject of debate and research. A definite role for volumetric MRI to aid the diagnosis of AD is not yet fully established. [36]"}
{"id": "article-17423_54", "title": "Alzheimer Disease -- Evaluation", "content": "Functional brain imaging techniques\u00a0such as Positron Emission Tomography\u00a0(PET), functional MRI (fMRI), and Single-Photon Emission Computed Tomography (SPECT) are becoming increasingly\u00a0valuable in\u00a0mapping patterns of dysfunction in smaller brain areas of the medial temporal and parietal lobes. While these functional brain imaging techniques hold promise for early detection and monitoring of the clinical progression of AD, their role in the definitive diagnosis of AD is not fully established yet.", "contents": "Alzheimer Disease -- Evaluation. Functional brain imaging techniques\u00a0such as Positron Emission Tomography\u00a0(PET), functional MRI (fMRI), and Single-Photon Emission Computed Tomography (SPECT) are becoming increasingly\u00a0valuable in\u00a0mapping patterns of dysfunction in smaller brain areas of the medial temporal and parietal lobes. While these functional brain imaging techniques hold promise for early detection and monitoring of the clinical progression of AD, their role in the definitive diagnosis of AD is not fully established yet."}
{"id": "article-17423_55", "title": "Alzheimer Disease -- Evaluation", "content": "Electroencephalogram (EEG) is generally not a helpful\u00a0diagnostic tool for\u00a0AD and other neurodegenerative disorders. The EEG findings in\u00a0AD\u00a0are typically normal. Sometimes, it may\u00a0reveal a generalized slowing of brainwave activity with no focal features. Neuropsychological testing is the most reliable method\u00a0for\u00a0detecting mild cognitive impairment (MCI) in its early\u00a0stages clinically.", "contents": "Alzheimer Disease -- Evaluation. Electroencephalogram (EEG) is generally not a helpful\u00a0diagnostic tool for\u00a0AD and other neurodegenerative disorders. The EEG findings in\u00a0AD\u00a0are typically normal. Sometimes, it may\u00a0reveal a generalized slowing of brainwave activity with no focal features. Neuropsychological testing is the most reliable method\u00a0for\u00a0detecting mild cognitive impairment (MCI) in its early\u00a0stages clinically."}
{"id": "article-17423_56", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "Over the past decade, significant progress has been made in developing neuroimaging and biochemical markers\u00a0for diagnosing preclinical and early clinical stages of AD. However, these\u00a0biomarkers are\u00a0not widely available for routine clinical practice and are\u00a0primarily utilized in AD research settings.", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. Over the past decade, significant progress has been made in developing neuroimaging and biochemical markers\u00a0for diagnosing preclinical and early clinical stages of AD. However, these\u00a0biomarkers are\u00a0not widely available for routine clinical practice and are\u00a0primarily utilized in AD research settings."}
{"id": "article-17423_57", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "With the\u00a0development\u00a0of specific treatments\u00a0for AD, especially monoclonal antibodies targeting\u00a0A\u03b2, the importance of these disease markers becomes even more pronounced. Before initiating AD-specific therapies, it becomes crucial to accurately diagnose the presence and progression of AD pathology in patients.", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. With the\u00a0development\u00a0of specific treatments\u00a0for AD, especially monoclonal antibodies targeting\u00a0A\u03b2, the importance of these disease markers becomes even more pronounced. Before initiating AD-specific therapies, it becomes crucial to accurately diagnose the presence and progression of AD pathology in patients."}
{"id": "article-17423_58", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "Fluorodeoxyglucose-PET (FDG-PET) is a valuable functional imaging biomarker that can\u00a0aid in the\u00a0early and differential diagnosis of AD. FDG-PET may\u00a0reveal specific metabolic impairments in certain brain regions,\u00a0particularly the hippocampi, in individuals with early or preclinical AD. [37] [38]", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. Fluorodeoxyglucose-PET (FDG-PET) is a valuable functional imaging biomarker that can\u00a0aid in the\u00a0early and differential diagnosis of AD. FDG-PET may\u00a0reveal specific metabolic impairments in certain brain regions,\u00a0particularly the hippocampi, in individuals with early or preclinical AD. [37] [38]"}
{"id": "article-17423_59", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "Amyloid PET\u00a0is an important in vivo surrogate for A\u03b2 pathology in the brain. It allows for the detection and visualization of amyloid deposition, a hallmark feature of AD.\u00a0Amyloid PET is more specific for the pathological diagnosis of AD compared to other neurodegenerative disorders. However, its utilization is limited because amyloid deposition\u00a0can be observed in normal elderly individuals. It best differentiates between neurodegenerative disorders caused by A\u03b2 deposition and those related to other protein abnormalities, such as the deposition of \u03b1-synuclein or tau. [38]", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. Amyloid PET\u00a0is an important in vivo surrogate for A\u03b2 pathology in the brain. It allows for the detection and visualization of amyloid deposition, a hallmark feature of AD.\u00a0Amyloid PET is more specific for the pathological diagnosis of AD compared to other neurodegenerative disorders. However, its utilization is limited because amyloid deposition\u00a0can be observed in normal elderly individuals. It best differentiates between neurodegenerative disorders caused by A\u03b2 deposition and those related to other protein abnormalities, such as the deposition of \u03b1-synuclein or tau. [38]"}
{"id": "article-17423_60", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "Cerebrospinal fluid (CSF) analysis is a helpful diagnostic tool in the preclinical stage of AD. It serves as a biomarker for AD pathology and can detect changes well before the onset of overt clinical symptoms. However, it does not help determine\u00a0the severity of AD.", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. Cerebrospinal fluid (CSF) analysis is a helpful diagnostic tool in the preclinical stage of AD. It serves as a biomarker for AD pathology and can detect changes well before the onset of overt clinical symptoms. However, it does not help determine\u00a0the severity of AD."}
{"id": "article-17423_61", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "The main\u00a0CSF biomarkers used in AD diagnosis are amyloid-beta 42 (A\u03b242), phosphorylated tau (p-tau), and total tau (t-tau). In AD, there is decreased CSF A\u03b242 and increased tau isoforms (both p-tau and t-tau).", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. The main\u00a0CSF biomarkers used in AD diagnosis are amyloid-beta 42 (A\u03b242), phosphorylated tau (p-tau), and total tau (t-tau). In AD, there is decreased CSF A\u03b242 and increased tau isoforms (both p-tau and t-tau)."}
{"id": "article-17423_62", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "The ratios of CSF biomarkers, such as A\u03b242/40, have provided a more accurate and sensitive index of the underlying amyloid-related pathology in patients. The increase in CSF p-tau and t-tau levels directly reflects tau aggregation within the brain in AD. [39] Genetic studies are\u00a0not routinely\u00a0recommended for the diagnosis of AD. However, they may be considered in specific cases for families with rare early-onset AD forms.", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. The ratios of CSF biomarkers, such as A\u03b242/40, have provided a more accurate and sensitive index of the underlying amyloid-related pathology in patients. The increase in CSF p-tau and t-tau levels directly reflects tau aggregation within the brain in AD. [39] Genetic studies are\u00a0not routinely\u00a0recommended for the diagnosis of AD. However, they may be considered in specific cases for families with rare early-onset AD forms."}
{"id": "article-17423_63", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "It is important to recognize\u00a0that\u00a0obtaining a definitive diagnosis of Alzheimer\u00a0dementia, despite\u00a0comprehensive\u00a0clinical evaluation and\u00a0testing, may not always be possible. Some patients may\u00a0exhibit\u00a0subjective\u00a0cognitive complaints\u00a0that can be objectively assessed but do not yet reach the\u00a0level of impairment that interferes with their\u00a0daily functioning. In such cases, the classification\u00a0may be\u00a0mild cognitive impairment (MCI) instead of dementia.", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. It is important to recognize\u00a0that\u00a0obtaining a definitive diagnosis of Alzheimer\u00a0dementia, despite\u00a0comprehensive\u00a0clinical evaluation and\u00a0testing, may not always be possible. Some patients may\u00a0exhibit\u00a0subjective\u00a0cognitive complaints\u00a0that can be objectively assessed but do not yet reach the\u00a0level of impairment that interferes with their\u00a0daily functioning. In such cases, the classification\u00a0may be\u00a0mild cognitive impairment (MCI) instead of dementia."}
{"id": "article-17423_64", "title": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD", "content": "MCI represents an intermediate stage between normal age-related cognitive changes and the more severe cognitive impairment seen in dementia. Many people with\u00a0MCI will develop some form of dementia within 5 to 7 years. [4]", "contents": "Alzheimer Disease -- Evaluation -- Imaging and Biochemical Markers of AD. MCI represents an intermediate stage between normal age-related cognitive changes and the more severe cognitive impairment seen in dementia. Many people with\u00a0MCI will develop some form of dementia within 5 to 7 years. [4]"}
{"id": "article-17423_65", "title": "Alzheimer Disease -- Treatment / Management -- Symptomatic Therapies of AD", "content": "Traditionally, there\u00a0has been no cure for AD, and symptomatic treatment remains the primary approach in everyday clinical practice. [40] [41] [42] Two categories of drugs are approved for treating\u00a0AD: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists.", "contents": "Alzheimer Disease -- Treatment / Management -- Symptomatic Therapies of AD. Traditionally, there\u00a0has been no cure for AD, and symptomatic treatment remains the primary approach in everyday clinical practice. [40] [41] [42] Two categories of drugs are approved for treating\u00a0AD: cholinesterase inhibitors and partial N-methyl D-aspartate (NMDA) antagonists."}
{"id": "article-17423_66", "title": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors", "content": "Cholinesterase inhibitors function\u00a0by increasing the levels of acetylcholine, a neurotransmitter that plays a role in\u00a0nerve cell communication and is involved in learning, memory, and cognitive functions. Within\u00a0this category, 3 drugs have received FDA approval for treating AD: donepezil, rivastigmine, and galantamine. [43] [44] [45] Donepezil: Medication of choice Used in AD with mild dementia Rapid and reversible inhibitor of acetylcholinesterase Once-daily dosing in the evening Rivastigmine: Used in MCI and mild dementia stages Slow, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase Available in an oral and transdermal formulation Galantamine: Approved in MCI and mild dementia stages Rapid, reversible inhibits of acetylcholinesterase Available as a twice-daily tablet or once-daily extended-release capsule Cannot be used in individuals with end-stage renal disease or severe liver dysfunction", "contents": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors. Cholinesterase inhibitors function\u00a0by increasing the levels of acetylcholine, a neurotransmitter that plays a role in\u00a0nerve cell communication and is involved in learning, memory, and cognitive functions. Within\u00a0this category, 3 drugs have received FDA approval for treating AD: donepezil, rivastigmine, and galantamine. [43] [44] [45] Donepezil: Medication of choice Used in AD with mild dementia Rapid and reversible inhibitor of acetylcholinesterase Once-daily dosing in the evening Rivastigmine: Used in MCI and mild dementia stages Slow, reversible inhibitor of acetylcholinesterase and butyrylcholinesterase Available in an oral and transdermal formulation Galantamine: Approved in MCI and mild dementia stages Rapid, reversible inhibits of acetylcholinesterase Available as a twice-daily tablet or once-daily extended-release capsule Cannot be used in individuals with end-stage renal disease or severe liver dysfunction"}
{"id": "article-17423_67", "title": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors", "content": "The most common side effects of cholinesterase inhibitors include\u00a0gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Due to an increase in\u00a0vagal tone, these medications can cause bradycardia, cardiac conduction defects, and syncope. They are contraindicated in patients with severe cardiac conduction abnormalities. Partial N-Methyl D-Aspartate (NMDA) Memantine", "contents": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors. The most common side effects of cholinesterase inhibitors include\u00a0gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Due to an increase in\u00a0vagal tone, these medications can cause bradycardia, cardiac conduction defects, and syncope. They are contraindicated in patients with severe cardiac conduction abnormalities. Partial N-Methyl D-Aspartate (NMDA) Memantine"}
{"id": "article-17423_68", "title": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors", "content": "Partial N-Methyl D-aspartate (NMDA) antagonist memantine blocks NMDA receptors, slowing down intracellular calcium accumulation. The FDA approves it for treating moderate to severe AD. Dizziness, body aches, headache, and constipation are common side effects. Memantine can be combined with cholinesterase inhibitors, such as donepezil, rivastigmine, or galantamine, especially in individuals with moderate to severe AD. [46]", "contents": "Alzheimer Disease -- Treatment / Management -- Cholinesterase Inhibitors. Partial N-Methyl D-aspartate (NMDA) antagonist memantine blocks NMDA receptors, slowing down intracellular calcium accumulation. The FDA approves it for treating moderate to severe AD. Dizziness, body aches, headache, and constipation are common side effects. Memantine can be combined with cholinesterase inhibitors, such as donepezil, rivastigmine, or galantamine, especially in individuals with moderate to severe AD. [46]"}
{"id": "article-17423_69", "title": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD", "content": "In the past, the treatment of AD\u00a0has primarily focused on managing the symptoms. By the time a patient is diagnosed with AD, the pathological process in the brain\u00a0has been present for over a decade. However,\u00a0with advancements in our\u00a0understanding of the pathophysiology of AD and improvements in diagnostic testing with imaging and biochemical markers, we can now detect\u00a0preclinical and presymptomatic stages of the disease, even in individuals with MCI.", "contents": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD. In the past, the treatment of AD\u00a0has primarily focused on managing the symptoms. By the time a patient is diagnosed with AD, the pathological process in the brain\u00a0has been present for over a decade. However,\u00a0with advancements in our\u00a0understanding of the pathophysiology of AD and improvements in diagnostic testing with imaging and biochemical markers, we can now detect\u00a0preclinical and presymptomatic stages of the disease, even in individuals with MCI."}
{"id": "article-17423_70", "title": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD", "content": "New and specific disease-modifying therapies are being developed, and the FDA has recently approved some. For example, Aducanemab was approved by the FDA in June 2020. The FDA recently approved Lecanemab. Donanemab is also expected to receive FDA approval soon. These monoclonal antibodies act by removing amyloid from the brain as immunotherapy.\u00a0Remternetug is\u00a0another one of these promising amyloid-targeting immunotherapy drugs in the pipeline. [47] Aducanemab received accelerated FDA approval in June 2020. It was shown to reduce amyloid-beta plaque in the brain. However, it missed the primary phase III trial endpoint of clinical improvement. [48] Lecanemab received accelerated FDA approval in January 2023. It reduced the amyloid-beta burden in the brain. The phase III trial showed\u00a0a 27% slowing of disease progression. [49] Donanemab is expected to receive FDA approval in 2023. It reduced the amyloid-beta burden in the brain and slowed cognitive decline by 35%. [50]", "contents": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD. New and specific disease-modifying therapies are being developed, and the FDA has recently approved some. For example, Aducanemab was approved by the FDA in June 2020. The FDA recently approved Lecanemab. Donanemab is also expected to receive FDA approval soon. These monoclonal antibodies act by removing amyloid from the brain as immunotherapy.\u00a0Remternetug is\u00a0another one of these promising amyloid-targeting immunotherapy drugs in the pipeline. [47] Aducanemab received accelerated FDA approval in June 2020. It was shown to reduce amyloid-beta plaque in the brain. However, it missed the primary phase III trial endpoint of clinical improvement. [48] Lecanemab received accelerated FDA approval in January 2023. It reduced the amyloid-beta burden in the brain. The phase III trial showed\u00a0a 27% slowing of disease progression. [49] Donanemab is expected to receive FDA approval in 2023. It reduced the amyloid-beta burden in the brain and slowed cognitive decline by 35%. [50]"}
{"id": "article-17423_71", "title": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD", "content": "Amyloid Related Imaging Abnormalities (ARIA) [51]", "contents": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD. Amyloid Related Imaging Abnormalities (ARIA) [51]"}
{"id": "article-17423_72", "title": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD", "content": "ARIA is an immune-mediated response to amyloid-targeting therapies in the cerebral vascular walls resulting in capillary leakage into perivascular spaces and hemorrhages of cortical and leptomeningeal arteries. There are\u00a02 radiological types of ARIA: ARIA edema (ARIA-E) and ARIA hemorrhage (ARIA-H).", "contents": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD. ARIA is an immune-mediated response to amyloid-targeting therapies in the cerebral vascular walls resulting in capillary leakage into perivascular spaces and hemorrhages of cortical and leptomeningeal arteries. There are\u00a02 radiological types of ARIA: ARIA edema (ARIA-E) and ARIA hemorrhage (ARIA-H)."}
{"id": "article-17423_73", "title": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD", "content": "ARIA is a known side effect associated with amyloid immunotherapies. Apolipoprotein E4 allele and cerebral amyloid angiopathy findings in brain MRI are the most substantial risk factors for developing ARIA in patients treated with amyloid immunotherapies. In the Aducanemab phase I/II trials, ARIA-E and ARIA-H were present in 26.1% to 26.7% and 26.1% to 30.5% of the patients, respectively. Notably, the majority of these patients were asymptomatic. [50]", "contents": "Alzheimer Disease -- Treatment / Management -- Disease Modifying Therapies of AD. ARIA is a known side effect associated with amyloid immunotherapies. Apolipoprotein E4 allele and cerebral amyloid angiopathy findings in brain MRI are the most substantial risk factors for developing ARIA in patients treated with amyloid immunotherapies. In the Aducanemab phase I/II trials, ARIA-E and ARIA-H were present in 26.1% to 26.7% and 26.1% to 30.5% of the patients, respectively. Notably, the majority of these patients were asymptomatic. [50]"}
{"id": "article-17423_74", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "In managing AD, addressing accompanying symptoms such as anxiety, depression, and psychosis is essential, especially in the mid to late stages of the\u00a0disease.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. In managing AD, addressing accompanying symptoms such as anxiety, depression, and psychosis is essential, especially in the mid to late stages of the\u00a0disease."}
{"id": "article-17423_75", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "It is advisable to avoid\u00a0tricyclic antidepressants because of their anticholinergic activity, which can worsen cognitive impairment. Antipsychotic medications should be used cautiously for acute agitation when other interventions have been exhausted and the patient's or caregiver's safety is at risk. Other medications are generally tried before consideration of antipsychotics. These generally include SSRI antidepressants such as citalopram and anticholinesterase such as donepezil.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. It is advisable to avoid\u00a0tricyclic antidepressants because of their anticholinergic activity, which can worsen cognitive impairment. Antipsychotic medications should be used cautiously for acute agitation when other interventions have been exhausted and the patient's or caregiver's safety is at risk. Other medications are generally tried before consideration of antipsychotics. These generally include SSRI antidepressants such as citalopram and anticholinesterase such as donepezil."}
{"id": "article-17423_76", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "Second-generation antipsychotics are generally favored over first-generation antipsychotics because of their safety and less extrapyramidal side effects. FDA just approved Brexpiprazole in May 2023 for treating agitation associated with dementia due to AD. [52] However, their limited benefits should be weighed against the small risks of stroke and increased mortality.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. Second-generation antipsychotics are generally favored over first-generation antipsychotics because of their safety and less extrapyramidal side effects. FDA just approved Brexpiprazole in May 2023 for treating agitation associated with dementia due to AD. [52] However, their limited benefits should be weighed against the small risks of stroke and increased mortality."}
{"id": "article-17423_77", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "The general principle in using antipsychotics is to use the lowest dose that may help the patient's agitation. Benzodiazepines should not be used because they may worsen delirium and agitation in these patients.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. The general principle in using antipsychotics is to use the lowest dose that may help the patient's agitation. Benzodiazepines should not be used because they may worsen delirium and agitation in these patients."}
{"id": "article-17423_78", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "Simple strategies\u00a0such as creating\u00a0a familiar and safe environment, monitoring and addressing personal comfort needs, providing security objects, redirecting attention, removing potentially hazardous items like doorknobs, and avoiding confrontational situations can be highly beneficial in managing behavioral issues.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. Simple strategies\u00a0such as creating\u00a0a familiar and safe environment, monitoring and addressing personal comfort needs, providing security objects, redirecting attention, removing potentially hazardous items like doorknobs, and avoiding confrontational situations can be highly beneficial in managing behavioral issues."}
{"id": "article-17423_79", "title": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD", "content": "Addressing mild sleep disturbances is essential to minimize caregiver burden and improve the quality of life for individuals with AD. Several non-pharmacological strategies can be\u00a0incorporated, such as\u00a0exposure to sunlight, providing daytime exercise, and establishing a bedtime routine. These interventions can help regulate the sleep-wake cycle and promote better sleep patterns. The expected benefits of these treatments are modest. Treatment should be stopped or modified if no significant benefits are seen or the patient experiences intolerable side effects. Regular aerobic exercise has been shown to slow the progression of AD.", "contents": "Alzheimer Disease -- Treatment / Management -- Other Management Strategies in AD. Addressing mild sleep disturbances is essential to minimize caregiver burden and improve the quality of life for individuals with AD. Several non-pharmacological strategies can be\u00a0incorporated, such as\u00a0exposure to sunlight, providing daytime exercise, and establishing a bedtime routine. These interventions can help regulate the sleep-wake cycle and promote better sleep patterns. The expected benefits of these treatments are modest. Treatment should be stopped or modified if no significant benefits are seen or the patient experiences intolerable side effects. Regular aerobic exercise has been shown to slow the progression of AD."}
{"id": "article-17423_80", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "The differential\u00a0diagnosis of Alzheimer dementia includes considering conditions such as pseudodementia or depression, Lewy body dementia, vascular dementia, and frontotemporal lobar degeneration. Other\u00a0disorders to be considered and excluded have age-associated memory impairment, alcohol or drug abuse, vitamin-B12 deficiency, individuals undergoing dialysis,\u00a0thyroid problems, and the potential impact of polypharmacy. [53]", "contents": "Alzheimer Disease -- Differential Diagnosis. The differential\u00a0diagnosis of Alzheimer dementia includes considering conditions such as pseudodementia or depression, Lewy body dementia, vascular dementia, and frontotemporal lobar degeneration. Other\u00a0disorders to be considered and excluded have age-associated memory impairment, alcohol or drug abuse, vitamin-B12 deficiency, individuals undergoing dialysis,\u00a0thyroid problems, and the potential impact of polypharmacy. [53]"}
{"id": "article-17423_81", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "Lewy Body Dementia (DLB): Approximately 15% of cases of dementia can be attributed to DLB. The DSM-5 includes it within Neurocognitive Disorders with Lewy Bodies. Histologically, patients with DLB have cortical Lewy bodies, and their concentration correlates with the severity of dementia. These bodies are\u00a0spherical intracytoplasmic inclusions with a dense circular eosinophilic core surrounded by loose fibrils. The core contains aggregates of proteins\u00a0\u03b1-synuclein\u00a0and ubiquitin.", "contents": "Alzheimer Disease -- Differential Diagnosis. Lewy Body Dementia (DLB): Approximately 15% of cases of dementia can be attributed to DLB. The DSM-5 includes it within Neurocognitive Disorders with Lewy Bodies. Histologically, patients with DLB have cortical Lewy bodies, and their concentration correlates with the severity of dementia. These bodies are\u00a0spherical intracytoplasmic inclusions with a dense circular eosinophilic core surrounded by loose fibrils. The core contains aggregates of proteins\u00a0\u03b1-synuclein\u00a0and ubiquitin."}
{"id": "article-17423_82", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "Patients with Lewy Body dementia have core clinical features (fluctuating cognition, visual hallucinations, \u22651\u00a0symptom of Parkinson disease with onset the development of cognitive decline), suggestive clinical features (REM sleep behavior disorder and severe antipsychotic sensitivity), and indicative biomarkers (123-MIBG demonstrates low uptake, SPECT or PET shows reduced dopamine transporter uptake in basal ganglia, and PSG shows REM sleep without atonia).", "contents": "Alzheimer Disease -- Differential Diagnosis. Patients with Lewy Body dementia have core clinical features (fluctuating cognition, visual hallucinations, \u22651\u00a0symptom of Parkinson disease with onset the development of cognitive decline), suggestive clinical features (REM sleep behavior disorder and severe antipsychotic sensitivity), and indicative biomarkers (123-MIBG demonstrates low uptake, SPECT or PET shows reduced dopamine transporter uptake in basal ganglia, and PSG shows REM sleep without atonia)."}
{"id": "article-17423_83", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "A probable\u00a0diagnosis is\u00a0made if a patient has\u00a02 core features or\u00a01 suggestive feature with\u00a01 or more core features. A possible diagnosis is given if the patient has only\u00a01 core feature or\u00a01 or more suggestive features. [54]", "contents": "Alzheimer Disease -- Differential Diagnosis. A probable\u00a0diagnosis is\u00a0made if a patient has\u00a02 core features or\u00a01 suggestive feature with\u00a01 or more core features. A possible diagnosis is given if the patient has only\u00a01 core feature or\u00a01 or more suggestive features. [54]"}
{"id": "article-17423_84", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "Frontotemporal Dementia (FTD): It accounts for 5% to 10% of all dementia cases and typically presents at a mean age of 53, more commonly affecting men than women. Patients with FTD experience personality and behavioral disturbances with or without language impairment, which\u00a0precede dementia with an insidious onset. The term \"Pick disease\"\u00a0was historically used for\u00a0FTD due to intraneuronal inclusions known as \"Pick bodies\" in histological findings. FTD\u00a0is categorized into\u00a02 subtypes: behavioral variant and language variant.", "contents": "Alzheimer Disease -- Differential Diagnosis. Frontotemporal Dementia (FTD): It accounts for 5% to 10% of all dementia cases and typically presents at a mean age of 53, more commonly affecting men than women. Patients with FTD experience personality and behavioral disturbances with or without language impairment, which\u00a0precede dementia with an insidious onset. The term \"Pick disease\"\u00a0was historically used for\u00a0FTD due to intraneuronal inclusions known as \"Pick bodies\" in histological findings. FTD\u00a0is categorized into\u00a02 subtypes: behavioral variant and language variant."}
{"id": "article-17423_85", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "For the behavioral variant, a possible diagnosis requires the presence of 3\u00a0of the following symptoms: disinhibition, apathy, loss of sympathy, stereotyped or compulsive behaviors, hyperorality, and decline in social cognition and executive abilities. The language variant has a decline in language ability. In addition to these symptoms, evidence of genetic mutation or frontal and temporal lobe involvement on CT or MRI is required for probable diagnosis. Importantly, patients with FTD\u00a0typically retain their visuospatial abilities despite the cognitive decline. [55]", "contents": "Alzheimer Disease -- Differential Diagnosis. For the behavioral variant, a possible diagnosis requires the presence of 3\u00a0of the following symptoms: disinhibition, apathy, loss of sympathy, stereotyped or compulsive behaviors, hyperorality, and decline in social cognition and executive abilities. The language variant has a decline in language ability. In addition to these symptoms, evidence of genetic mutation or frontal and temporal lobe involvement on CT or MRI is required for probable diagnosis. Importantly, patients with FTD\u00a0typically retain their visuospatial abilities despite the cognitive decline. [55]"}
{"id": "article-17423_86", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "Dialysis Dementia: Dialysis dementia is a neurologic complication\u00a0that can arise from chronic dialysis treatment. It can be due to various factors, such as vascular causes (as dialysis patients\u00a0are at\u00a0a\u00a0higher risk of stroke), metabolic abnormalities, or the dialysis process. In the past, it was\u00a0associated\u00a0with aluminum toxicity, but now, its occurrence has decreased with the use of aluminum-free substances. The\u00a0precise mechanism behind dialysis dementia remains unclear. [56]", "contents": "Alzheimer Disease -- Differential Diagnosis. Dialysis Dementia: Dialysis dementia is a neurologic complication\u00a0that can arise from chronic dialysis treatment. It can be due to various factors, such as vascular causes (as dialysis patients\u00a0are at\u00a0a\u00a0higher risk of stroke), metabolic abnormalities, or the dialysis process. In the past, it was\u00a0associated\u00a0with aluminum toxicity, but now, its occurrence has decreased with the use of aluminum-free substances. The\u00a0precise mechanism behind dialysis dementia remains unclear. [56]"}
{"id": "article-17423_87", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "It is important to note that the initial symptoms of AD can vary depending\u00a0on the age of diagnosis. [57] Memory impairment remains the most common initial symptom of AD. Among\u00a0patients aged 70 to 79, approximately 90% present with memory impairment as the first symptom. This percentage\u00a0increases to 94% for patients\u00a0older than\u00a079. However, in patients diagnosed with AD younger than 60, around 74% initially exhibit memory impairment, with about a quarter presenting with impaired judgment and visuospatial functions. Overall, EOAD patients are more likely to have atypical AD presentations than those with LOAD (see Chart . Cognitive Symptom Presentation). [58] Some atypical presentations of\u00a0AD include:", "contents": "Alzheimer Disease -- Differential Diagnosis. It is important to note that the initial symptoms of AD can vary depending\u00a0on the age of diagnosis. [57] Memory impairment remains the most common initial symptom of AD. Among\u00a0patients aged 70 to 79, approximately 90% present with memory impairment as the first symptom. This percentage\u00a0increases to 94% for patients\u00a0older than\u00a079. However, in patients diagnosed with AD younger than 60, around 74% initially exhibit memory impairment, with about a quarter presenting with impaired judgment and visuospatial functions. Overall, EOAD patients are more likely to have atypical AD presentations than those with LOAD (see Chart . Cognitive Symptom Presentation). [58] Some atypical presentations of\u00a0AD include:"}
{"id": "article-17423_88", "title": "Alzheimer Disease -- Differential Diagnosis", "content": "The multidomain amnestic syndrome affects multiple areas of cognition,\u00a0especially language and spatial orientation, with relative memory sparing in the early stages. Posterior cortical atrophy, characterized by\u00a0progressive cortical visual impairment with features such as simultagnosia, object and space perception deficits, acalculia, alexia, and oculomotor apraxia, with relative sparing of anterograde memory, non-visual language function, behavior, and personality. Neuroimaging shows occipitoparietal or occipitotemporal atrophy. [59] Primary progressive aphasia(PPA) is characterized by progressive language difficulty with relative sparing of memory and other cognitive functions in early disease. While most patients with PPA have a pathological diagnosis of frontotemporal dementia, the logopenic form of PPA has typical AD pathology. [60] Dysexecutive or frontal variant patients have impairment in executive functions relative to memory loss.", "contents": "Alzheimer Disease -- Differential Diagnosis. The multidomain amnestic syndrome affects multiple areas of cognition,\u00a0especially language and spatial orientation, with relative memory sparing in the early stages. Posterior cortical atrophy, characterized by\u00a0progressive cortical visual impairment with features such as simultagnosia, object and space perception deficits, acalculia, alexia, and oculomotor apraxia, with relative sparing of anterograde memory, non-visual language function, behavior, and personality. Neuroimaging shows occipitoparietal or occipitotemporal atrophy. [59] Primary progressive aphasia(PPA) is characterized by progressive language difficulty with relative sparing of memory and other cognitive functions in early disease. While most patients with PPA have a pathological diagnosis of frontotemporal dementia, the logopenic form of PPA has typical AD pathology. [60] Dysexecutive or frontal variant patients have impairment in executive functions relative to memory loss."}
{"id": "article-17423_89", "title": "Alzheimer Disease -- Staging -- Preclinical or Presymptomatic", "content": "In this preclinical stage, individuals are asymptomatic, but there is definite laboratory evidence of AD pathology. Identifying the biomarkers can\u00a0aid in diagnosing Alzheimer disease at this stage. Low levels of amyloid and increased tau proteins in CSF are potential biomarkers, although they are not specific to AD.\u00a0Combining various\u00a0variables, such as ApoE4 positivity, scores on cognitive tests like the paired associates immediate recall test and digits symbol substitution test, increased tau protein in CSF, and measurements of right entorhinal cortex thickness and right hippocampal volume on MRI, can help predict the progression to MCI from this preclinical stage.", "contents": "Alzheimer Disease -- Staging -- Preclinical or Presymptomatic. In this preclinical stage, individuals are asymptomatic, but there is definite laboratory evidence of AD pathology. Identifying the biomarkers can\u00a0aid in diagnosing Alzheimer disease at this stage. Low levels of amyloid and increased tau proteins in CSF are potential biomarkers, although they are not specific to AD.\u00a0Combining various\u00a0variables, such as ApoE4 positivity, scores on cognitive tests like the paired associates immediate recall test and digits symbol substitution test, increased tau protein in CSF, and measurements of right entorhinal cortex thickness and right hippocampal volume on MRI, can help predict the progression to MCI from this preclinical stage."}
{"id": "article-17423_90", "title": "Alzheimer Disease -- Staging -- Mild Cognitive Impairment", "content": "In this stage, patients\u00a0experience MCI\u00a0with either memory or non-memory domain impairment, such as executive ability or language function.\u00a0Despite these cognitive changes, these\u00a0individuals continue to work, socialize, and function independently.\u00a0The progression rate from MCI to dementia is approximately\u00a010% per year. Risk factors for this progression include the severity of impairment at the time of diagnosis and other established risk factors for AD.", "contents": "Alzheimer Disease -- Staging -- Mild Cognitive Impairment. In this stage, patients\u00a0experience MCI\u00a0with either memory or non-memory domain impairment, such as executive ability or language function.\u00a0Despite these cognitive changes, these\u00a0individuals continue to work, socialize, and function independently.\u00a0The progression rate from MCI to dementia is approximately\u00a010% per year. Risk factors for this progression include the severity of impairment at the time of diagnosis and other established risk factors for AD."}
{"id": "article-17423_91", "title": "Alzheimer Disease -- Staging -- Dementia", "content": "In this stage, patients\u00a0experience incapacitating memory impairment with notable language changes, including\u00a0anomia, paraphasic errors,\u00a0reduced\u00a0spontaneous verbal output, and a tendency\u00a0to use circumlocution\u00a0to compensate for\u00a0forgotten words. Additionally, a decline in visuospatial abilities\u00a0leads to difficulties in navigation within familiar surroundings and\u00a0constructional apraxia.", "contents": "Alzheimer Disease -- Staging -- Dementia. In this stage, patients\u00a0experience incapacitating memory impairment with notable language changes, including\u00a0anomia, paraphasic errors,\u00a0reduced\u00a0spontaneous verbal output, and a tendency\u00a0to use circumlocution\u00a0to compensate for\u00a0forgotten words. Additionally, a decline in visuospatial abilities\u00a0leads to difficulties in navigation within familiar surroundings and\u00a0constructional apraxia."}
{"id": "article-17423_92", "title": "Alzheimer Disease -- Staging -- Dementia", "content": "Around 20% to 40% of patients with AD may experience delusions. Visual hallucinations are more common, although auditory and olfactory hallucinations\u00a0can also occur. Disruptive behaviors\u00a0are prevalent\u00a0in almost 50% of the patients. Patients\u00a0often lose their typical circadian sleep-wake pattern in this stage, leading to fragmented sleep. Additionally, motor vehicle crashes are\u00a0more frequent in patients with AD.", "contents": "Alzheimer Disease -- Staging -- Dementia. Around 20% to 40% of patients with AD may experience delusions. Visual hallucinations are more common, although auditory and olfactory hallucinations\u00a0can also occur. Disruptive behaviors\u00a0are prevalent\u00a0in almost 50% of the patients. Patients\u00a0often lose their typical circadian sleep-wake pattern in this stage, leading to fragmented sleep. Additionally, motor vehicle crashes are\u00a0more frequent in patients with AD."}
{"id": "article-17423_93", "title": "Alzheimer Disease -- Prognosis", "content": "Alzheimer disease is a relentlessly progressive condition. On average, individuals aged 65 or older diagnosed with AD may have a life expectancy of about 4 to 8 years. However, some individuals with AD may live up to 20 years after the\u00a0initial signs of the disease.", "contents": "Alzheimer Disease -- Prognosis. Alzheimer disease is a relentlessly progressive condition. On average, individuals aged 65 or older diagnosed with AD may have a life expectancy of about 4 to 8 years. However, some individuals with AD may live up to 20 years after the\u00a0initial signs of the disease."}
{"id": "article-17423_94", "title": "Alzheimer Disease -- Prognosis", "content": "The overall decline in physical and immune function, coupled with impaired mobility and difficulty swallowing, makes Alzheimer's patients vulnerable to infections, particularly pneumonia, which is the most common cause of death. [61]", "contents": "Alzheimer Disease -- Prognosis. The overall decline in physical and immune function, coupled with impaired mobility and difficulty swallowing, makes Alzheimer's patients vulnerable to infections, particularly pneumonia, which is the most common cause of death. [61]"}
{"id": "article-17423_95", "title": "Alzheimer Disease -- Complications", "content": "According to CDC's National Center for Health Statistics 2023, AD is the 6th leading cause of death, with nearly 120,000 deaths annually. AD\u00a0predominantly affects individuals\u00a0over 65, putting them at higher risk of experiencing complications that can significantly impact their health and well-being. Complications\u00a0associated with AD can be broadly categorized into\u00a0mental/behavioral and physical challenges. They are listed as follows: [62] [63]", "contents": "Alzheimer Disease -- Complications. According to CDC's National Center for Health Statistics 2023, AD is the 6th leading cause of death, with nearly 120,000 deaths annually. AD\u00a0predominantly affects individuals\u00a0over 65, putting them at higher risk of experiencing complications that can significantly impact their health and well-being. Complications\u00a0associated with AD can be broadly categorized into\u00a0mental/behavioral and physical challenges. They are listed as follows: [62] [63]"}
{"id": "article-17423_96", "title": "Alzheimer Disease -- Complications -- Mental/Behavioral", "content": "Depression is\u00a0a prevalent comorbidity among patients with AD, adding to the complexity of managing their condition. Common symptoms of depression in patients with AD include mood changes, sleep disturbances, social withdrawal, and difficulty concentrating. Agitation and delirium, including sundowning, are common occurrences in the more advanced stages of AD, posing challenges for patients and caregivers. Managing these symptoms is essential for ensuring the safety and comfort of individuals with AD. However, the use of antipsychotic medications to treat these issues has been associated with increased mortality and other adverse effects. Wandering", "contents": "Alzheimer Disease -- Complications -- Mental/Behavioral. Depression is\u00a0a prevalent comorbidity among patients with AD, adding to the complexity of managing their condition. Common symptoms of depression in patients with AD include mood changes, sleep disturbances, social withdrawal, and difficulty concentrating. Agitation and delirium, including sundowning, are common occurrences in the more advanced stages of AD, posing challenges for patients and caregivers. Managing these symptoms is essential for ensuring the safety and comfort of individuals with AD. However, the use of antipsychotic medications to treat these issues has been associated with increased mortality and other adverse effects. Wandering"}
{"id": "article-17423_97", "title": "Alzheimer Disease -- Complications -- Physical", "content": "Fever and infections, particularly respiratory and urinary infections, are prevalent among elderly individuals with AD. Swallowing difficulties can lead to aspiration pneumonia, further complicating their health condition. Dehydration and malnutrition Falls Bladder and bowel problems", "contents": "Alzheimer Disease -- Complications -- Physical. Fever and infections, particularly respiratory and urinary infections, are prevalent among elderly individuals with AD. Swallowing difficulties can lead to aspiration pneumonia, further complicating their health condition. Dehydration and malnutrition Falls Bladder and bowel problems"}
{"id": "article-17423_98", "title": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation", "content": "Rehabilitation and physical activity\u00a0play crucial roles in treating and preventing dementia. Regular physical activity has been shown to benefit individuals with dementia significantly. It can\u00a0improve\u00a0cognitive function, especially executive functioning,\u00a0which helps\u00a0reduce the\u00a0fall risk and\u00a0enhances the ability to perform activities of daily living. Furthermore, physical activity has reduced the incidence of\u00a0neuropsychiatric symptoms like depression. [64]", "contents": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation. Rehabilitation and physical activity\u00a0play crucial roles in treating and preventing dementia. Regular physical activity has been shown to benefit individuals with dementia significantly. It can\u00a0improve\u00a0cognitive function, especially executive functioning,\u00a0which helps\u00a0reduce the\u00a0fall risk and\u00a0enhances the ability to perform activities of daily living. Furthermore, physical activity has reduced the incidence of\u00a0neuropsychiatric symptoms like depression. [64]"}
{"id": "article-17423_99", "title": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation", "content": "Although specific clinical practice guidelines for exercise in dementia patients are not yet established, ongoing research continuously strives to determine the\u00a0most effective type, intensity, and duration of exercise. Studies suggest moderate\u00a0to high-intensity exercise may offer greater benefits than lower-intensity activities. [65] [66]", "contents": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation. Although specific clinical practice guidelines for exercise in dementia patients are not yet established, ongoing research continuously strives to determine the\u00a0most effective type, intensity, and duration of exercise. Studies suggest moderate\u00a0to high-intensity exercise may offer greater benefits than lower-intensity activities. [65] [66]"}
{"id": "article-17423_100", "title": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation", "content": "Caregivers and the care team play a critical role in ensuring continuity of care and providing the necessary support for dementia patients. Due to limitations in education retention, regular reinforcement of information and guidance is essential to help individuals with dementia maintain their functional abilities and quality of life.", "contents": "Alzheimer Disease -- Postoperative and Rehabilitation Care -- Rehabilitation. Caregivers and the care team play a critical role in ensuring continuity of care and providing the necessary support for dementia patients. Due to limitations in education retention, regular reinforcement of information and guidance is essential to help individuals with dementia maintain their functional abilities and quality of life."}
{"id": "article-17423_101", "title": "Alzheimer Disease -- Deterrence and Patient Education", "content": "Given its high prevalence, the care of patients with AD is of global concern. However, there are no specific requirements for professional development education or accreditation for healthcare providers in AD care.", "contents": "Alzheimer Disease -- Deterrence and Patient Education. Given its high prevalence, the care of patients with AD is of global concern. However, there are no specific requirements for professional development education or accreditation for healthcare providers in AD care."}
{"id": "article-17423_102", "title": "Alzheimer Disease -- Deterrence and Patient Education", "content": "It is crucial to prioritize patient and care provider education to enhance the quality of care for AD patients. An interprofessional team-based approach involving medical doctors, social workers, therapists, and family members is essential for comprehensive care. Additionally, bridging the gap between theoretical education and its practical application in real-life settings is vital to ensure adequate care delivery for AD patients. [67]", "contents": "Alzheimer Disease -- Deterrence and Patient Education. It is crucial to prioritize patient and care provider education to enhance the quality of care for AD patients. An interprofessional team-based approach involving medical doctors, social workers, therapists, and family members is essential for comprehensive care. Additionally, bridging the gap between theoretical education and its practical application in real-life settings is vital to ensure adequate care delivery for AD patients. [67]"}
{"id": "article-17423_103", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Alzheimer's disease (AD) is a progressive neurodegenerative disorder\u00a0characterized by cognitive and behavioral impairments that eventually\u00a0disrupt\u00a0daily activities. Unfortunately, AD has no cure, and its progression varies from person to person. Early diagnosis of Alzheimer disease remains challenging, as no definitive laboratory or imaging tests are available for confirmation.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Alzheimer's disease (AD) is a progressive neurodegenerative disorder\u00a0characterized by cognitive and behavioral impairments that eventually\u00a0disrupt\u00a0daily activities. Unfortunately, AD has no cure, and its progression varies from person to person. Early diagnosis of Alzheimer disease remains challenging, as no definitive laboratory or imaging tests are available for confirmation."}
{"id": "article-17423_104", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "The drugs\u00a0used to treat AD\u00a0provide only modest benefits in\u00a0mild disease but\u00a0often come with\u00a0numerous side effects that patients may not tolerate. The impact of AD\u00a0 is not limited to the individual affected; it also significantly affects the family, as patients may exhibit wandering behavior, falls, behavioral issues, and memory loss. These challenges often lead to patients\u00a0requiring\u00a0institutional care due to the increasing difficulty of managing their condition\u00a0at home.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. The drugs\u00a0used to treat AD\u00a0provide only modest benefits in\u00a0mild disease but\u00a0often come with\u00a0numerous side effects that patients may not tolerate. The impact of AD\u00a0 is not limited to the individual affected; it also significantly affects the family, as patients may exhibit wandering behavior, falls, behavioral issues, and memory loss. These challenges often lead to patients\u00a0requiring\u00a0institutional care due to the increasing difficulty of managing their condition\u00a0at home."}
{"id": "article-17423_105", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Given the complex\u00a0nature of\u00a0Alzheimer's disease, an interprofessional team approach is highly recommended.\u00a0Various guidelines and recommendations have been\u00a0developed to address the\u00a0approach,\u00a0monitoring, and\u00a0treatment of\u00a0patients with\u00a0Alzheimer dementia. While no single\u00a0measure can prevent or\u00a0halt\u00a0the disease's progression, a collaborative effort among healthcare professionals is crucial in ensuring the safety and quality of life for individuals with AD. Several healthcare workers play critical roles in caring for patients with AD to ensure their well-being and dignity. A few key healthcare workers are as follows:", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Given the complex\u00a0nature of\u00a0Alzheimer's disease, an interprofessional team approach is highly recommended.\u00a0Various guidelines and recommendations have been\u00a0developed to address the\u00a0approach,\u00a0monitoring, and\u00a0treatment of\u00a0patients with\u00a0Alzheimer dementia. While no single\u00a0measure can prevent or\u00a0halt\u00a0the disease's progression, a collaborative effort among healthcare professionals is crucial in ensuring the safety and quality of life for individuals with AD. Several healthcare workers play critical roles in caring for patients with AD to ensure their well-being and dignity. A few key healthcare workers are as follows:"}
{"id": "article-17423_106", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Physical\u00a0therapists and occupational therapists\u00a0for therapy and exercise. There is now ample evidence that exercise can help reduce the progression of the disease. [65]", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Physical\u00a0therapists and occupational therapists\u00a0for therapy and exercise. There is now ample evidence that exercise can help reduce the progression of the disease. [65]"}
{"id": "article-17423_107", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Nurses play a crucial role in educating patients and their families about medications, lifestyle changes, and performing daily living activities. They also support self-reporting any worsening symptoms, helping monitor the patient's condition, and managing their care.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Nurses play a crucial role in educating patients and their families about medications, lifestyle changes, and performing daily living activities. They also support self-reporting any worsening symptoms, helping monitor the patient's condition, and managing their care."}
{"id": "article-17423_108", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Pharmacists ensure\u00a0the safe and appropriate use of medications, avoiding polypharmacy and minimizing the risk of adverse effects.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Pharmacists ensure\u00a0the safe and appropriate use of medications, avoiding polypharmacy and minimizing the risk of adverse effects."}
{"id": "article-17423_109", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Clinicians, including physicians and neurologists, monitor the patient's progress, conduct regular evaluations, and adjust treatment plans as needed. They work to enhance the patient's overall quality of life and manage any medical complications that may arise.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Clinicians, including physicians and neurologists, monitor the patient's progress, conduct regular evaluations, and adjust treatment plans as needed. They work to enhance the patient's overall quality of life and manage any medical complications that may arise."}
{"id": "article-17423_110", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Caregivers are essential team members,\u00a0providing direct support to the patient in daily living activities, managing behavioral challenges, and offering emotional and physical assistance.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Caregivers are essential team members,\u00a0providing direct support to the patient in daily living activities, managing behavioral challenges, and offering emotional and physical assistance."}
{"id": "article-17423_111", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Social workers help ensure the patient has a robust\u00a0support system addressing social and emotional needs.\u00a0They may assist in accessing community resources, support groups, and respite care for caregivers.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Social workers help ensure the patient has a robust\u00a0support system addressing social and emotional needs.\u00a0They may assist in accessing community resources, support groups, and respite care for caregivers."}
{"id": "article-17423_112", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Dietitians ensure the patient\u00a0maintains a\u00a0healthy diet tailored to their needs.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Dietitians ensure the patient\u00a0maintains a\u00a0healthy diet tailored to their needs."}
{"id": "article-17423_113", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes", "content": "Mental health nurses\u00a0specialize in addressing the psychological and emotional aspects of AD, providing support to both the patient and their caregivers as they cope with the challenges of the disorder.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes. Mental health nurses\u00a0specialize in addressing the psychological and emotional aspects of AD, providing support to both the patient and their caregivers as they cope with the challenges of the disorder."}
{"id": "article-17423_114", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes -- Outcomes", "content": "Alzheimer disease initially\u00a0manifests with impaired memory, but as it progresses, individuals may develop a range of severe cognitive and behavioral symptoms like depression, anxiety, anger, irritability, insomnia, and paranoia. As the disease progresses, most will require assistance with daily living activities. The disease's relentless course often necessitates increasing aid with daily living activities as cognitive and functional abilities decline. In the advanced stages, even basic tasks like walking can become challenging, and many individuals may face difficulties with eating or develop swallowing problems, putting them at risk of aspiration pneumonia.", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes -- Outcomes. Alzheimer disease initially\u00a0manifests with impaired memory, but as it progresses, individuals may develop a range of severe cognitive and behavioral symptoms like depression, anxiety, anger, irritability, insomnia, and paranoia. As the disease progresses, most will require assistance with daily living activities. The disease's relentless course often necessitates increasing aid with daily living activities as cognitive and functional abilities decline. In the advanced stages, even basic tasks like walking can become challenging, and many individuals may face difficulties with eating or develop swallowing problems, putting them at risk of aspiration pneumonia."}
{"id": "article-17423_115", "title": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes -- Outcomes", "content": "The time from diagnosis to death in AD is variable, with some individuals\u00a0passing away within\u00a05 years,\u00a0while others may\u00a0survive for up to 10 years or more. However, throughout\u00a0the course of the disease, the quality of life is\u00a0significantly\u00a0impaired. While an interprofessional approach to managing patients with AD is recommended, an analysis of several studies\u00a0indicates that this approach has not considerably impacted patient care. Nevertheless, because of the heterogeneity of previous studies, more robust\u00a0and well-designed research\u00a0will be required to determine\u00a0the most effective approach for managing these patients. [68]", "contents": "Alzheimer Disease -- Enhancing Healthcare Team Outcomes -- Outcomes. The time from diagnosis to death in AD is variable, with some individuals\u00a0passing away within\u00a05 years,\u00a0while others may\u00a0survive for up to 10 years or more. However, throughout\u00a0the course of the disease, the quality of life is\u00a0significantly\u00a0impaired. While an interprofessional approach to managing patients with AD is recommended, an analysis of several studies\u00a0indicates that this approach has not considerably impacted patient care. Nevertheless, because of the heterogeneity of previous studies, more robust\u00a0and well-designed research\u00a0will be required to determine\u00a0the most effective approach for managing these patients. [68]"}
{"id": "article-17423_116", "title": "Alzheimer Disease -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Alzheimer Disease -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}